Evidence map›Paper›PMID 35745761›Full record

ArticlePharmaceutics2022

Effects of Drug Physicochemical Properties on In-Situ Forming Implant Polymer Degradation and Drug Release Kinetics.

Jordan B Joiner, Alka Prasher, Isabella C Young, Jessie Kim, Roopali Shrivastava, Panita Maturavongsadit, Soumya Rahima Benhabbour

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Ultra-long-acting injectable, biodegradable, and removable in-situ forming implant with cabotegravir for HIV prevention.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Ultra-Long-Term Delivery of Hydrophilic Drugs Using InjectablebioRxiv : the preprint server for biology · 2024
    Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Long-acting injectable multipurpose prevention technology for prevention of HIV and unplanned pregnancy.Journal of controlled release : official journal of the Controlled Release Society · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jordan B JoinerDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0003-0663-949X
Alka PrasherJoint Department of Biomedical Engineering, University of North Carolina and North Carolina State University, Chapel Hill, NC 27599, USA.
Isabella C YoungDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Jessie KimEshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Roopali ShrivastavaJoint Department of Biomedical Engineering, University of North Carolina and North Carolina State University, Chapel Hill, NC 27599, USA.ORCID 0000-0001-7723-4639
Panita MaturavongsaditDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Soumya Rahima BenhabbourDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-4738-5871
University of North Carolina at Chapel Hill · US

Funding

North Carolina Translational & Clinical Sciences Institute (NC TraCS)KL2TR001109 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, CAREY, TIMOTHY S · 2013 to 2017
$5.7M
Ultra-Long-Acting Polymeric Injectable Multi-Purpose Prevention Technology for Contraception and HIV PreventionR01AI162246 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BENHABBOUR, SOUMYA RAHIMA · 2021 to 2025
$3.7M
Development and pre-clinical evaluation of a novel Polymer-Based In-Situ Forming Implant (ISFI) for Long-Acting HIV PrEPR01AI131430 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BENHABBOUR, SOUMYA RAHIMA, KOVAROVA, MARTINA · 2017 to 2020
$2.4M
National Institute of Infectious Diseases R01AI131430National Institute of Infectious Diseases R01AI162246National Science Foundation DGE-1650116NCATS NIH HHS KL2 TR001109NCATS NIH HHS KL2TR001109-04NIAID NIH HHS R01 AI131430NIAID NIH HHS R01 AI162246
6 · The paper itself

Abstract

In-situ forming implants (ISFIs) represent a simple, tunable, and biodegradable polymer-based platform for long-acting drug delivery. However, drugs with different physicochemical properties and physical states in the polymer-solvent system exhibit different drug release kinetics. Although a few limited studies have been performed attempting to elucidate these effects, a large, systematic study has not been performed until now. The purpose of this study was to characterize the in vitro drug release of 12 different small molecule drugs with differing logP and pKa values from ISFIs. Drug release was compared with polymer degradation as measured by lactic acid (LA) release and change in poly(DL-lactide-

Indexed as

biodegradable implantscontrolled drug releasedrug deliverydrug physicochemical propertiesinjectablein-situlong-actingpoly(lactic-co-glycolic acid)

Identifiers

PMID35745761
PMCPMC9228340
OpenAlexW4281682194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.